Merck KGaA/€MRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
- Ticker
- €MRK
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 62,136
- Headquarters
- Darmstadt, Germany
- Website
- www.merckgroup.com
Merck KGaA Metrics
BasicAdvanced
€62B
26.18
€5.45
0.79
€2.20
1.54%
Price and volume
Market cap
€62B
Beta
0.79
52-week high
€148.60
52-week low
€100.70
Average daily volume
308K
Dividend rate
€2.20
Financial strength
Current ratio
1.695
Quick ratio
0.988
Long term debt to equity
0.37
Total debt to equity
0.406
Dividend payout ratio (TTM)
43.80%
Interest coverage (TTM)
9.08%
Profitability
EBITDA (TTM)
5,587
Gross margin (TTM)
59.09%
Net profit margin (TTM)
11.21%
Operating margin (TTM)
17.61%
Effective tax rate (TTM)
21.35%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
8.13%
Valuation
Price to earnings (TTM)
26.181
Price to revenue (TTM)
2.934
Price to book
2.06
Price to tangible book (TTM)
14.94
Price to free cash flow (TTM)
24.053
Free cash flow yield (TTM)
4.16%
Free cash flow per share (TTM)
5.932
Dividend yield (TTM)
1.54%
Forward dividend yield
1.54%
Growth
Revenue change (TTM)
-0.40%
Earnings per share change (TTM)
-17.27%
3-year revenue growth (CAGR)
-1.42%
10-year revenue growth (CAGR)
4.16%
3-year earnings per share growth (CAGR)
-8.35%
10-year earnings per share growth (CAGR)
5.48%
10-year dividend per share growth (CAGR)
7.68%
What the Analysts think about Merck KGaA
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Analyst projections of the future price of Merck KGaA stock.
Bulls say / Bears say
Merck beat Q2 earnings expectations and raised its 2026 adjusted EBITDA guidance to €5.9bn–€6.3bn from €5.7bn–€6.1bn. This points to stronger near-term earnings momentum. (Reuters)
Life Science grew 8% organically in Q2, with Process Solutions up 14.7% as demand for drug-manufacturing supplies stayed strong. Merck raised the division’s 2026 organic sales growth outlook to 5%–7%. (Merck KGaA)
Electronics’ semiconductor unit grew 17% organically in Q2 as demand for advanced chip materials linked to AI applications rose. Merck raised the division’s 2026 organic sales growth outlook to 6%–9%. (Merck KGaA, Reuters)
Healthcare remains a drag: Merck expects organic sales to fall 2%–4% in 2026 and assumes no US Mavenclad sales from August as generic competition intensifies. (Merck KGaA)
Reported earnings weakened in Q2: EBIT fell 15.5% and profit after tax fell 24.7% year on year, despite growth in adjusted EBITDA. This leaves reported profitability under pressure. (American Pharmaceutical Review)
Some Life Science growth may be temporary: management said Q2 benefited from unusually strong purchasing activity in Asia-Pacific, with the uplift beginning to normalise. This makes the recent growth rate less certain to persist. (ROIC AI, Watch List News)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Merck KGaA Financial Performance
Revenues and expenses
Merck KGaA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Merck KGaA
AllEURUSDGBP
Fund name | Fund size | €MRK weighting |
|---|---|---|
iShares Dax ESG€EXIA | €127M | 1.72% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 1.12% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 1.12% |
iShares Core DAX€EXS1 | €8.8B | 1.09% |
iShares Core DAX€EXIC | €75M | 1.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.